Cohen & Steers, Inc. (CNS)

Executive Summary / Key Takeaways

• Cohen & Steers has reached a critical turning point after nine consecutive quarters of net outflows, posting firm-wide inflows in Q3 2024 and maintaining positive momentum through 2025, signaling that the macro headwinds from rising rates have finally become tailwinds for its core real asset strategies.

• The February 2025 launch of three active ETFs represents more than product expansion—it is a strategic assault on the fastest-growing segment of wealth management, with $54 million in Q2 net inflows already capturing RIAs who previously couldn't access CNS's strategies, directly addressing the industry's $1 trillion active ETF shift.

• Financial performance validates the inflection: Q3 2025 operating margins hit 34.5% while effective fee rates increased across all vehicle types, demonstrating pricing power that defies the industry's race-to-zero fee compression and proving the value of specialized real asset expertise.

• The company's hybrid listed-private real estate strategy, exemplified by its market-leading CNS REIT (12.2% returns vs. 5% peer average), positions CNS to capture a massive portfolio rebalancing as institutional investors confront the hidden opportunity cost of illiquidity in private markets.

• The central risk-reward tension: CNS's focused real asset moat generates superior returns and client loyalty, but its $3.2 billion market cap and $90.9 billion AUM remain dwarfed by Blackstone's $1.24 trillion, leaving it vulnerable to competitive pressure and cyclical downturns in rate-sensitive sectors.

Setting the Scene: The Real Asset Specialist in a Changing Macro

Cohen & Steers, founded in 1986 and headquartered in New York, has spent nearly four decades building what amounts to a luxury goods franchise in asset management. While competitors chased scale through acquisition and product proliferation, CNS cultivated deep expertise in a narrow but valuable niche: real assets and alternative income. This includes listed and private real estate, preferred securities, infrastructure, resource equities, and multi-strategy solutions. The company doesn't manage everything; it manages what matters in an inflationary, higher-rate environment.

The business model is elegantly simple: generate revenue through investment advisory and administration fees based on assets under management. In Q3 2025, this core revenue stream hit $133.6 million, up 6.6% year-over-year. This growth occurred despite a broader asset management industry struggling with outflows and fee compression. CNS achieved it by doing what it has always done: delivering superior performance in specialized strategies that institutional and wealth clients cannot replicate internally.

The macro backdrop has transformed from headwind to tailwind. For nine quarters starting in Q1 2022, the Federal Reserve's rate hiking cycle punished rate-sensitive real assets, triggering $800 million in known redemptions as clients rebalanced to fixed income. But regime change creates opportunity. As management stated, "the era of ultra-low interest rates is gone, inflation is stickier, fixed income allocations have been reestablished given higher yields. And there is a greater need for true diversification." This isn't just commentary—it's a direct explanation for why Q3 2024 marked the inflection point. Real assets are no longer an afterthought; they're a necessity for portfolios dominated by overvalued equities and correlated bonds.

CNS sits in a unique position within the industry value chain. Unlike Blackstone (BX), which pursues scale through massive private deals, or T. Rowe Price (TROW), which offers broad active management, CNS occupies the high-touch, high-value intersection of liquidity and real asset exposure. Its competitive moat isn't size—it's specificity. When institutional investors need listed real estate expertise or preferred securities management, CNS's 89% AUM outperformance and 90% four- or five-star Morningstar ratings make it the obvious choice. This positioning translates directly into pricing power: open-end fund effective fee rates increased to 67.5 basis points in Q3 2025 from 66.2 basis points a year prior, a seemingly small shift that represents millions in incremental revenue without adding a single dollar of AUM.

Technology, Products, and Strategic Differentiation: Solving the Liquidity Problem

CNS's product innovation in 2025 addresses a fundamental industry problem: the opportunity cost of illiquidity. For years, institutional investors accepted private real estate's lock-ups in pursuit of return premiums. But as management's research will show in the second half of 2025, "the presence of the illiquidity return premium is taken as a given but the data indicates it has been more inconsistent than reported." Specifically, private real estate has delivered negative illiquidity returns while infrastructure shows only neutral premiums. This undermines the entire rationale for allocating to illiquid strategies.

The solution is a hybrid approach that CNS is pioneering. In May 2025, the company launched a tactical listed and private real estate strategy with IDR Investment Management. This integrated vehicle aims for higher returns, reduced risk, lower drawdowns, and improved liquidity compared to core private real estate alone. The significance is profound: CNS can now offer institutions the best of both worlds—private real estate's diversification benefits with listed REITs' liquidity and alpha generation. This isn't just a new product; it's a structural advantage that competitors cannot easily replicate because it requires deep expertise in both listed and private markets, a capability CNS has methodically built over decades.

The ETF launch represents an even more direct attack on the wealth channel's evolution. In February 2025, CNS introduced its first three active ETFs covering U.S. real estate, global preferreds, and natural resource equities. These aren't thematic plays—they're core strategies seeded with firm capital and designed to capture the 43% of advisors who expect ETFs to replace most open-end fund allocations. The early results validate the strategy: $54 million in Q2 net inflows brought total AUM to $133 million, with particular strength in natural resource equities. More importantly, these flows include RIAs who exclusively use ETFs—money CNS would "never have ever touched" before.

This product expansion directly addresses the wealth channel's fastest-growing segment. The RIA segment is expanding at rates far exceeding traditional wirehouses, and CNS's Q4 2024 realignment of its U.S. wealth distribution team to engage cross-channel creates a direct sales path. Being live on Schwab (SCHW), Pershing, and Fidelity platforms provides access to the majority of the RIA market. The implication for the stock is clear: CNS is no longer dependent on institutional flows alone. It has unlocked a $1 trillion active ETF market where its specialized strategies can command premium fees and generate sticky, growing relationships.

Financial Performance & Segment Dynamics: Margin Expansion Through Mix

CNS's Q3 2025 financial results tell a story of successful navigation through a turbulent environment. Revenue of $133.6 million grew 6.6% year-over-year, driven by higher average AUM and effective fee rate expansion. The operating margin of 34.5% improved from 33.7% in the prior year period, demonstrating operational leverage that defies the industry's typical margin pressure. This proves that specialization and performance can overcome scale disadvantages.

The segment breakdown reveals the engine of growth. Open-end funds generated $74.2 million in revenue, up 11.2% year-over-year, with an effective fee rate of 67.5 basis points. This 1.3 basis point increase from the prior year reflects a mix shift toward higher-fee strategies where CNS has pricing power. Institutional accounts, while only growing 0.8% to $33.2 million, maintained fee rate expansion to 38.2 basis points. Even closed-end funds, often seen as a legacy business, grew 1.9% with fee rates at 89.2 basis points. The implication is that CNS isn't competing on price—it's competing on performance, and clients are willing to pay for alpha.

The wealth channel's contribution becomes clear when examining flow patterns. Open-end funds posted $285 million in Q2 net inflows, marking the fourth consecutive quarter of positive flows. This $1.1 billion annualized pace is particularly impressive given that Morningstar data shows most strategy categories experiencing outflows. CNS's market share in active open-end fund AUM is increasing across U.S. real estate, global real estate, preferreds, and global listed infrastructure. The reason is performance: 89% of AUM outperformed benchmarks in Q2 2025, with 94% outperforming over one year and over 95% for three, five, and ten years.

Institutional flows tell a more nuanced story. Advisory accounts saw $412 million in net outflows in Q2, driven by rebalancing and strategic allocation shifts rather than performance issues. However, the unfunded pipeline stands at $776 million, with 52% in U.S. real estate and 26% in global listed infrastructure. This represents future revenue that is already contracted but not yet earning fees. The $500 million in known redemptions, while concerning, are tactical adjustments rather than performance-driven terminations. The net pipeline of $275 million suggests the institutional business has stabilized and could contribute to growth as these mandates fund.

The balance sheet provides strategic flexibility. Net liquid assets of $339.7 million and a $100 million revolving credit facility give CNS firepower for seed investments and co-investments in private vehicles. The company has committed $175 million to investment vehicles, with $58.9 million unfunded as of September 2025. This capital intensity is a deliberate strategy to align interests with clients and capture economics from private markets. The implication for investors is that CNS is investing in future growth while maintaining a strong liquidity position—net cash used in operating activities was $121.5 million for nine months, but this included $264.1 million in net purchases of investments within consolidated funds, a sign of active capital deployment rather than operational weakness.

Outlook, Management Guidance, and Execution Risk

Management's guidance for 2025 reflects confidence in the strategic pivot while acknowledging execution challenges. The compensation ratio is expected to remain at 40.5%, indicating disciplined cost control even as the company invests in distribution. G&A expenses are projected to increase 7-8% for the full year, driven by infrastructure investments including foreign office upgrades and ETF launch costs. After 2025, management expects G&A growth to moderate to mid-single digits, suggesting the heavy investment phase will conclude. This signals that margin expansion can accelerate as revenue growth outpaces expense growth.

The macro outlook is cautiously optimistic. Management expects core U.S. inflation to remain above the Fed's long-term target, with tariffs adding pressure. This stagflationary environment should favor real assets, which have "less sensitivity to tariffs and flow and growth, attractive relative valuations, and liquidity." U.S. REIT earnings are projected to decline only 0-1% from tariff impacts versus 10% for the S&P 500. Infrastructure faces 2-3% direct pressure, but natural resource equities could see 10-15% EPS pressure offset by higher commodity prices. The implication is that CNS's strategy mix is well-positioned for the current regime, but natural resource exposure could create headwinds.

Execution risk centers on three areas. First, the ETF ramp must accelerate from $133 million to meaningful scale. Management is "very pleased" with early flows but acknowledges it's "still early days." The success of round two ETF launches and potential inorganic growth opportunities will determine whether CNS can capture the 43% of advisors shifting to ETFs. Second, the private real estate strategy must deploy capital effectively. CNS REIT's 12.2% return versus 5% peer average provides validation, but scaling from five shopping centers to a diversified portfolio requires disciplined execution. Third, the institutional pipeline must convert to funded mandates. The $776 million unfunded pipeline is encouraging, but management admits "we need to translate those into real mandates."

International expansion presents both opportunity and risk. The Singapore office, opened 1.5 years ago, provides a hedge against Hong Kong uncertainty and access to Asian clients. Japan's investment renaissance hasn't yet translated to flows, but the Daiwa Asset Management partnership positions CNS for eventual uptake. Europe remains slower, while Middle East activity has cooled from prior years. Diversification is key: CNS cannot rely solely on U.S. wealth channel growth, and international success will be critical for long-term sustainability.

Risks and Asymmetries: Where the Thesis Can Break

The most material risk to the investment thesis is CNS's scale disadvantage versus mega-managers. Blackstone's $1.24 trillion AUM and T. Rowe Price's $1.77 trillion dwarf CNS's $90.9 billion. This size gap creates several vulnerabilities. First, larger competitors can absorb fee compression more easily, forcing CNS to defend premium pricing through performance alone. Second, distribution power concentrates with scale—wirehouses and large institutions may prefer one-stop-shop solutions from TROW or AB (AllianceBernstein (AB)) over specialized managers. Third, technology investment requires scale; while CNS spends on data and analytics, BX can deploy hundreds of millions in AI and automation. The implication is that CNS must maintain performance excellence just to preserve market share, let alone grow.

Interest rate sensitivity remains a critical vulnerability. Despite management's optimism about "stable long-term interest rates, even if at a higher level," real estate and preferred securities remain rate-sensitive. The 10-year Treasury's 80 basis point rise to 4.6% in early 2025 pressured REIT valuations even as fundamentals remained positive. If rates rise further due to persistent inflation or Fed policy shifts, CNS's core strategies could face renewed outflows. This risk is amplified by the company's concentration in real assets—unlike diversified peers, CNS lacks large equity or fixed income businesses to offset real estate weakness.

Execution risk on new initiatives is substantial. The ETF launch, while promising, faces intense competition. Passive REIT ETFs charge fees as low as 0.07% compared to CNS's active strategies at likely 0.50-0.75%. While CNS's performance justifies the premium, advisors converting from open-end funds to ETFs may demand fee concessions. The private real estate strategy requires meaningful co-investment, with $58.9 million in unfunded commitments tying up capital that could otherwise be returned to shareholders. If deployment is slow or returns disappoint, the strategy could drag ROE.

Client concentration risk, while not extreme, exists. The $500 million in known redemptions represents significant AUM, and the $776 million pipeline is concentrated in U.S. real estate (52%) and global infrastructure (26%). A downturn in either sector could stall growth. Additionally, the wealth channel's reliance on RIA growth means CNS is betting on a specific distribution trend that could reverse if regulatory or market conditions shift.

On the positive side, meaningful asymmetries exist. If inflation remains sticky and investors rotate from overvalued equities (Shiller P/E near all-time highs) to real assets, CNS could see flows accelerate beyond management's base case. The company's research on illiquidity costs could become industry-standard, driving institutional allocations toward listed solutions. A successful second round of ETF launches or a strategic acquisition could catapult CNS into the top tier of active ETF providers. The balance sheet provides optionality—$339.7 million in net liquid assets and a $100 million credit line could fund a transformative acquisition if market dislocations create opportunities.

Valuation Context: Premium for a Reason

At $62.65 per share, CNS trades at 19.6x trailing earnings and 5.3x enterprise value to revenue. These multiples sit at a premium to some peers but at a discount to the company's own historical performance potential. The P/E of 19.6x is reasonable for a business generating 31.1% ROE and 34.5% operating margins. The EV/Revenue of 5.3x reflects the market's recognition of CNS's specialized positioning, though it trails Blackstone's 17.3x, which benefits from private market scarcity premium.

Cash flow metrics are more telling. With $96.7 million in annual operating cash flow and $85.0 million in free cash flow, CNS generates substantial cash relative to its $3.2 billion market cap. The 3.97% dividend yield, supported by a 76.8% payout ratio, provides income while investors wait for the growth inflection to accelerate. The debt-to-equity ratio of 0.24 and current ratio of 5.04 demonstrate a fortress balance sheet that can withstand market volatility and fund growth initiatives.

Peer comparisons highlight CNS's niche premium. T. Rowe Price trades at 11.5x P/E with 18.7% ROE—lower multiples reflecting its generalist positioning and slower growth. AllianceBernstein's 13.8x P/E and 19.8% ROE (on adjusted basis) show similar dynamics. Blackstone commands a 43.5x P/E due to its private market dominance and 26.5% ROE. CNS sits in the middle: more expensive than generalists but cheaper than pure-play alternatives, reflecting its hybrid public-private model.

The key valuation question is whether CNS deserves a premium for its real asset focus. With 89% of AUM outperforming benchmarks and 90% of open-end funds rated 4- or 5-star by Morningstar, the performance track record supports premium pricing. If the ETF strategy scales to $1-2 billion and the private real estate business generates carried interest, revenue growth could accelerate from mid-single digits to high-single or low-double digits, justifying current multiples through earnings growth rather than multiple expansion.

Conclusion: The Specialist's Moment

Cohen & Steers stands at an inflection point where nearly four decades of specialized real asset expertise is finally aligning with macro conditions that favor its core competencies. The nine-quarter outflow cycle that began with the Fed's rate hikes has reversed, and the company's strategic investments—in active ETFs, hybrid listed-private strategies, and wealth channel distribution—are beginning to bear fruit. The financial evidence is clear: expanding operating margins, rising effective fee rates, and positive net flows across key segments demonstrate that the specialist model can thrive even against scale-driven competitors.

The central thesis hinges on execution. CNS must scale its ETF business from $133 million to billions while maintaining premium fees. It must deploy $58.9 million in private real estate commitments without diluting returns. And it must convert its $776 million institutional pipeline into funded mandates before clients rebalance again. These are not trivial tasks, but the company's 89% AUM outperformance and fortress balance sheet provide the tools.

The risk-reward asymmetry is compelling. Downside is limited by a 3.97% dividend yield, strong liquidity, and a business model that has proven resilient through multiple rate cycles. Upside could be significant if inflation persists, driving asset allocation shifts toward real assets, or if the ETF strategy captures even a small slice of the $1 trillion active ETF market. Unlike generalist asset managers, CNS doesn't need to win every allocation—just the ones where real asset expertise matters. In an environment where portfolio construction is being rethought from first principles, that specialization may prove more valuable than scale.

For investors, the critical variables to monitor are ETF asset growth, private real estate deployment pace, and institutional pipeline conversion. If these metrics accelerate in 2026, the current 19.6x P/E will look like a bargain for a business generating 31% ROE with a widening moat. If they stall, the premium valuation could compress quickly. The next twelve months will determine whether CNS's moment as the real asset specialist is fleeting or foundational.